Clustering data with hclust algorithm for (Study ST004296)

Reversed phase NEGATIVE ION MODE (Analysis AN007143)
MetaboliteStructureF1F2
LysoPC(18:1(9Z)/0:0)_negative_modeME11660940.181.54
PI(20:3(6,8,11)-OH(5)/20:0)_negative_modeME11661210.401.40
CL(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0/16:0)_negative_modeME11661100.821.13
PE(20:1(11Z)/22:0)_negative_modeME11661020.971.02
CL(18:2(9Z,12Z)/18:2(9Z,11Z)/16:0/16:0)_negative_modeME11661110.881.10
Cer(d18:1/23:0)_negative_modeME11660920.901.07
Cer(d18:1/25:0)_negative_modeME11661090.921.05
SM(d18:1/17:0)_negative_modeME11661071.260.83
PC(20:3(5Z,8Z,11Z)/P-18:1(11Z))_negative_modeME11660971.300.83
PC(22:1(13Z)/15:0)_negative_modeME11661151.300.80
SM(d18:1/16:0(2OH))_negative_modeME11661041.280.81
PI(20:1(11Z)/15:0)_negative_modeME11661201.390.74
PC(20:3(5Z,8Z,11Z)/20:0)_negative_modeME11661131.330.75
PE-NMe(16:1(9Z)/22:2(13Z,16Z))_negative_modeME11661171.340.74
LacCer(d18:1/24:1(15Z))_negative_modeME11661121.080.95
PC(14:1(9Z)/18:1(9Z))_negative_modeME11660961.100.93
Cer(d18:1/16:0)_negative_modeME11660911.090.94
PC(20:3(5Z,8Z,11Z)/P-18:0)_negative_modeME11661141.090.94
Cer(d18:1/14:0)_negative_modeME11660901.060.96
GlcCer(d18:1/16:0)_negative_modeME11660931.040.97
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))_negative_modeME11660991.120.84
Cer(d16:1/16:0)_negative_modeME11660891.220.85
PC(14:0/15:0)_negative_modeME11660951.230.85
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/16:1(9Z))_negative_modeME11660981.230.85
SM(d18:1/14:0)_negative_modeME11661031.180.88
SM(d17:2(4E,8Z)/20:3(8Z,11Z,14Z)-2OH(5,6))_negative_modeME11661221.210.86
SM(d18:1/16:0)_negative_modeME11661051.190.87
SM(d18:1/20:0)_negative_modeME11661081.200.87
PC(O-18:0/18:2(9Z,12Z))_negative_modeME11661001.130.92
PE(14:0/18:1(9Z))_negative_modeME11661011.150.90
PI(16:0/22:3(10Z,13Z,16Z))_negative_modeME11661191.150.90
PE(20:3(5Z,8Z,11Z)/P-18:0)_negative_modeME11661161.170.89
PI(16:0/20:4(8Z,11Z,14Z,17Z))_negative_modeME11661181.160.89
SM(d18:1/16:1(9Z))_negative_modeME11661061.160.89

Factors:

F1Sample source:hASCs | Treatment:Osteogenic conditions
F2Sample source:hASCs | Treatment:Proliferation conditions
Data matrix
  logo